(R)-Perharidine 1
| Code | Size | Price |
|---|
| AG-MR-C0013-M001 | 1 mg | £80.00 |
Quantity:
| AG-MR-C0013-M005 | 5 mg | £245.00 |
Quantity:
| AG-MR-C0013-M025 | 25 mg | £685.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
-20°C
Documents
Further Information
Appearance:
White to off-white solid.
CAS:
1133437-80-5
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep under inert gas.Protect from light.
Hazards:
H319
InChi:
InChI=1S/C25H30N6O/c1-4-20(15-32)29-23-13-22(24-25(30-23)31(16-28-24)17(2)3)27-14-18-8-10-19(11-9-18)21-7-5-6-12-26-21/h5-13,16-17,20,32H,4,14-15H2,1-3H3,(H2,27,29,30)/t20-/m1/s1
InChiKey:
VGHHVXRBOQENRA-HXUWFJFHSA-N
Long Description:
Chemical. CAS: 1133437-80-5. Formula: C25H30N6O. MW: 430.6. Potent and selective inhibitor of cyclin dependent kinases CDK1, CDK2, CDK5 and CDK9. Apoptosis inducer. Inhibits the proliferation of various cancer cell lines. Casein kinase 1 (CK1delta/epsilon) inhibitor. Potential anti-inflammatory compound. Potential antidiabetic compound.
Molecular Formula:
C25H30N6O
Molecular Weight:
430.6
Package Type:
Vial
Precautions:
P280, P305, P351, P338
Product Description:
Potent and selective inhibitor of cyclin dependent kinases CDK1, CDK2, CDK5 and CDK9 [1]. Apoptosis inducer [1]. Inhibits the proliferation of various cancer cell lines [1]. Casein kinase 1 (CK1delta/epsilon) inhibitor [1]. Potential anti-inflammatory compound. Potential antidiabetic compound.
Purity:
>95% (NMR)
Signal word:
Warning
SMILES:
CC[C@H](CO)NC1=CC(NCC2=CC=CC=C2)=C2N=CN(C(C)C)C2=N1
Solubility Chemicals:
Soluble in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Perharidines as CDK inhibitors: L. Meijer, et al.; Patent WO2009034475A2 (2009)
Related Products
| Product Name | Product Code | Supplier | (S)-Perharidine 1 | AG-MR-C0012 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aftin-4 | AG-MR-C0014 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aftin-5 | AG-MR-C0015 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||